Shoshany Ohad, Mano Roy, Margel David, Baniel Jack, Yossepowitch Ofer
Department of Urology, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Urology, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Urol Oncol. 2014 Jan;32(1):40.e17-22. doi: 10.1016/j.urolonc.2013.04.009. Epub 2013 Aug 2.
To identify predictors of the absence of detrusor muscle in bladder tumor specimens and analyze its effect on clinical outcome as an indicator of resection quality.
The bladder cancer database of a tertiary medical center was queried for patients who underwent complete transurethral resection of bladder tumor (TURBT) between 2008 and 2009. Study end points were absence of detrusor muscle in the surgical specimen and its association with disease recurrence/progression.
Detrusor muscle in the surgical specimen was found in 265 of the 332 study patients (79%). The likelihood of finding muscle increased with higher clinical stage (Odds Ratio [OR]-1.8), higher tumor grade (OR-3), larger tumor size (OR-3.2), multifocal disease (OR-1.7), and nonpapillary morphology (OR-2.3). History of bladder cancer, surgeon's experience, and tumor location in the bladder had no effect. In the whole study population, neither tumor recurrence nor disease progression was associated with absence of detrusor muscle. In patients with T1 tumors, absence of detrusor muscle in the specimen was associated with higher early recurrence rate but not worse long-term outcome.
Absence of detrusor muscle in TURBT specimens is not determined by the technical difficulty of the procedure or surgical experience. Surgeons are more prone to obtain deep muscle in large, nonpapillary-appearing tumors, likely reflecting efforts to attain accurate staging in these cases. The presence or absence of detrusor muscle may serve as a surrogate of resection quality in patients with T1 tumors, but its general applicability to the overall population of patients undergoing TURBT remains questionable.
确定膀胱肿瘤标本中无逼尿肌的预测因素,并分析其作为切除质量指标对临床结果的影响。
查询一家三级医疗中心的膀胱癌数据库,以获取2008年至2009年间接受膀胱肿瘤完全经尿道切除术(TURBT)的患者。研究终点为手术标本中无逼尿肌及其与疾病复发/进展的关联。
332例研究患者中有265例(79%)手术标本中发现有逼尿肌。发现肌肉的可能性随着临床分期升高(优势比[OR]-1.8)、肿瘤分级升高(OR-3)、肿瘤尺寸增大(OR-3.2)、多灶性疾病(OR-1.7)和非乳头状形态(OR-2.3)而增加。膀胱癌病史、外科医生经验和肿瘤在膀胱中的位置无影响。在整个研究人群中,肿瘤复发和疾病进展均与无逼尿肌无关。在T1期肿瘤患者中,标本中无逼尿肌与早期复发率较高相关,但与长期预后较差无关。
TURBT标本中无逼尿肌并非由手术技术难度或手术经验决定。外科医生在处理大的、非乳头状外观的肿瘤时更倾向于获取深部肌肉,这可能反映了在这些病例中为准确分期所做的努力。逼尿肌的有无可作为T1期肿瘤患者切除质量的替代指标,但其对接受TURBT的所有患者的普遍适用性仍存疑问。